Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Asthma unmasked with tumor necrosis factor-α-blocking drugs.

Guilleminault L, Carré P, Beau-Salinas F, Taillé C, Dieudé P, Crestani B, Diot P, Marchand-Adam S.

Chest. 2011 Oct;140(4):1068-71. doi: 10.1378/chest.10-2350.

PMID:
21972387
2.

Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?

Kilic O, Kasapcopur O, Camcioglu Y, Cokugras H, Arisoy N, Akcakaya N.

Rheumatol Int. 2012 Sep;32(9):2675-9. doi: 10.1007/s00296-011-2030-8. Epub 2011 Jul 26.

PMID:
21789614
3.

Distinctive histopathologic phenotype in resection specimens from patients with Crohn's disease receiving anti-TNF-α therapy.

Schaeffer DF, Walsh JC, Kirsch R, Waterman M, Silverberg MS, Riddell RH.

Hum Pathol. 2014 Sep;45(9):1928-35. doi: 10.1016/j.humpath.2014.05.016. Epub 2014 Jun 12.

PMID:
25022570
4.

Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia.

Navarra SV, Tang B, Lu L, Lin HY, Mok CC, Asavatanabodee P, Suwannalai P, Hussein H, Rahman MU.

Int J Rheum Dis. 2014 Mar;17(3):291-8. doi: 10.1111/1756-185X.12188. Epub 2013 Oct 16.

5.

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.

Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A.

Arthritis Res Ther. 2011 Jun 20;13(3):R94. doi: 10.1186/ar3369.

6.

Adalimumab in the therapy of uveitis in childhood.

Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M.

Br J Ophthalmol. 2007 Mar;91(3):319-24. Epub 2006 Oct 11.

7.

T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.

Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED.

Am J Gastroenterol. 2013 Jan;108(1):99-105. doi: 10.1038/ajg.2012.334. Epub 2012 Oct 2.

PMID:
23032984
8.

Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors.

Bradford RD, Pettit AC, Wright PW, Mulligan MJ, Moreland LW, McLain DA, Gnann JW, Bloch KC.

Clin Infect Dis. 2009 Sep 15;49(6):924-7. doi: 10.1086/605498.

9.

Psoriasiform reactions to anti-tumor necrosis factor α therapy.

Nguyen K, Vleugels RA, Velez NF, Merola JF, Qureshi AA.

J Clin Rheumatol. 2013 Oct;19(7):377-81. doi: 10.1097/RHU.0b013e3182a702e8.

PMID:
24048106
10.

Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study.

Lanternier F, Tubach F, Ravaud P, Salmon D, Dellamonica P, Bretagne S, Couret M, Bouvard B, Debandt M, Gueit I, Gendre JP, Leone J, Nicolas N, Che D, Mariette X, Lortholary O; Research Axed on Tolerance of Biotherapies Group..

Chest. 2013 Sep;144(3):990-8. doi: 10.1378/chest.12-2820.

PMID:
23744173
11.

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.

Collamer AN, Battafarano DF.

Semin Arthritis Rheum. 2010 Dec;40(3):233-40. doi: 10.1016/j.semarthrit.2010.04.003. Epub 2010 Jun 26. Review.

PMID:
20580412
12.

[Alopecia areata during anti-TNF alpha therapy: Nine cases].

Le Bidre E, Chaby G, Martin L, Perrussel M, Sassolas B, Sigal ML, Kaassis C, Lespessailles E, Nseir A, Estève E.

Ann Dermatol Venereol. 2011;138(4):285-93. doi: 10.1016/j.annder.2011.01.047. Epub 2011 Mar 27. French.

PMID:
21497255
13.

Autoantibodies in psoriatic patients treated with anti-TNF-α therapy.

Bardazzi F, Odorici G, Virdi A, Antonucci VA, Tengattini V, Patrizi A, Balestri R.

J Dtsch Dermatol Ges. 2014 May;12(5):401-6. doi: 10.1111/ddg.12339.

PMID:
24797746
14.

Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.

Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.

Int J Rheum Dis. 2012 Jun;15(3):330-5. doi: 10.1111/j.1756-185X.2012.01715.x. Epub 2012 Feb 13.

PMID:
22709496
15.

Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.

Bonafede M, Fox KM, Watson C, Princic N, Gandra SR.

Adv Ther. 2012 Aug;29(8):664-74. doi: 10.1007/s12325-012-0037-5. Epub 2012 Aug 8.

PMID:
22886712
16.

The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.

Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD.

Ann Rheum Dis. 2008 May;67(5):710-2. Epub 2007 Dec 13.

PMID:
18079191
17.

Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.

Calvo-Río V, Blanco R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, Hernandez MV, Hernandez Garfella M, Valls Pascual E, Martínez-Costa L, Sellas-Fernández A, Cordero Coma M, Díaz-Llopis M, Gallego R, Salom D, García Serrano JL, Ortego N, Herreras JM, Fonollosa A, García-Aparicio AM, Maíz O, Blanco A, Torre I, Fernández-Espartero C, Jovani V, Peiteado-Lopez D, Pato E, Cruz J, Fernández-Cid C, Aurrecoechea E, García M, Caracuel MA, Montilla C, Atanes A, Hernandez FF, Insua S, González-Suárez S, Sánchez-Andrade A, Gamero F, Linares L, Romero-Bueno F, García AJ, Almodovar R, Minguez E, Carrasco Cubero C, Olive A, Vázquez J, Ruiz Moreno O, Jiménez-Zorzo F, Manero J, Muñoz Fernández S, Rueda-Gotor J, González-Gay MA.

Rheumatology (Oxford). 2014 Dec;53(12):2223-31. doi: 10.1093/rheumatology/keu266. Epub 2014 Jul 4.

PMID:
24996907
18.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

19.

Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases.

Hernández MV, Sanmartí R, Cañete JD, Descalzo MA, Alsina M, Carmona L, Gomez-Reino JJ; BIOBADASER 2.0 Study Group..

Arthritis Care Res (Hoboken). 2013 Dec;65(12):2024-31. doi: 10.1002/acr.22096.

20.

Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action.

Carroll MB, Forgione MA.

Clin Rheumatol. 2010 Sep;29(9):1021-9. doi: 10.1007/s10067-010-1523-2. Epub 2010 Jun 16. Review.

PMID:
20556450

Supplemental Content

Support Center